MA58700B1 - Souche de cutibacterium acnes et utilisations médicales associées - Google Patents

Souche de cutibacterium acnes et utilisations médicales associées

Info

Publication number
MA58700B1
MA58700B1 MA58700A MA58700A MA58700B1 MA 58700 B1 MA58700 B1 MA 58700B1 MA 58700 A MA58700 A MA 58700A MA 58700 A MA58700 A MA 58700A MA 58700 B1 MA58700 B1 MA 58700B1
Authority
MA
Morocco
Prior art keywords
strain
medical uses
cutibacterium acnes
associated medical
acnes strain
Prior art date
Application number
MA58700A
Other languages
English (en)
Inventor
Franca VERGALITO
Sonia Longo Sormani
Irene MAGNIFICO
Laura PIETRANGELO
Roberto Maria Antonio Di Marco
Marco Alfio CUTULI
Noemi VENDITTI
Giulio PETRONIO PETRONIO
Original Assignee
Aileens Pharma S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aileens Pharma S.R.L. filed Critical Aileens Pharma S.R.L.
Publication of MA58700B1 publication Critical patent/MA58700B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/06—Lysis of microorganisms
    • C12N1/066—Lysis of microorganisms by physical processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La présente invention concerne une souche bactérienne sélectionnée de Cutibacterium acnes et/ou une paroi cellulaire de celle-ci ou un post-biotique de la souche et des utilisations médicales ou nutritionnelles associées. L'invention concerne également des compositions pharmaceutiques ou nutritionnelles contenant la souche, la paroi cellulaire ou le post-biotique de celle-ci pour la prévention ou le traitement de maladies inflammatoires telles que la dermatite, le psoriasis ou les infections, en particulier les infections fongiques ou bactériennes de la peau ou des muqueuses.
MA58700A 2020-02-18 2021-02-18 Souche de cutibacterium acnes et utilisations médicales associées MA58700B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT102020000003233A IT202000003233A1 (it) 2020-02-18 2020-02-18 Ceppo batterico e suoi usi medici
PCT/EP2021/054083 WO2021165434A1 (fr) 2020-02-18 2021-02-18 Souche de cutibacterium acnes et utilisations médicales associées
EP21711182.2A EP4107293B1 (fr) 2020-02-18 2021-02-18 Souche de cutibacterium acnes et utilisations médicales associées

Publications (1)

Publication Number Publication Date
MA58700B1 true MA58700B1 (fr) 2025-04-30

Family

ID=70804885

Family Applications (1)

Application Number Title Priority Date Filing Date
MA58700A MA58700B1 (fr) 2020-02-18 2021-02-18 Souche de cutibacterium acnes et utilisations médicales associées

Country Status (24)

Country Link
US (1) US12508288B2 (fr)
EP (1) EP4107293B1 (fr)
JP (1) JP7832676B2 (fr)
KR (1) KR20220149543A (fr)
CN (1) CN115698258A (fr)
AU (1) AU2021225048A1 (fr)
BR (1) BR112022015153A2 (fr)
CA (1) CA3167099A1 (fr)
CO (1) CO2022013143A2 (fr)
ES (1) ES2983028T3 (fr)
HR (1) HRP20240892T1 (fr)
HU (1) HUE067226T2 (fr)
IL (2) IL326688A (fr)
IT (1) IT202000003233A1 (fr)
MA (1) MA58700B1 (fr)
MD (1) MD4107293T2 (fr)
MX (1) MX2022009744A (fr)
PH (1) PH12022552059A1 (fr)
PL (1) PL4107293T3 (fr)
RS (1) RS65788B1 (fr)
SA (1) SA522440072B1 (fr)
SM (1) SMT202400348T1 (fr)
WO (1) WO2021165434A1 (fr)
ZA (1) ZA202208862B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230392127A1 (en) * 2020-10-21 2023-12-07 Kangstem Biotech Co., Ltd. Method for construction of atopic dermatitis model by using pluripotent stem cell-derived skin organoid
IT202100013292A1 (it) * 2021-05-21 2022-11-21 Aileens Pharma S R L Parete cellulare batterica legata a mucopolisaccaride suoi utilizzi e processo per la sua produzione
CN118475341A (zh) * 2021-10-27 2024-08-09 希杰生物科技株式会社 用于预防或改善炎症性皮肤病的包含丙酸杆菌属菌株的化妆品组合物
WO2023075430A1 (fr) * 2021-10-27 2023-05-04 씨제이바이오사이언스 주식회사 Composition destinée à prévenir, à atténuer ou à traiter des maladies inflammatoires cutanées, comprenant une souche de cutibacterium
GB2623078B (en) * 2022-10-03 2025-04-16 Univ Brunel Prevention and/or treatment of wound infection
WO2024165954A1 (fr) * 2023-02-06 2024-08-15 Johnson & Johnson Consumer Inc. Compositions biomimétiques, prébiotiques, probiotiques et postbiotiques de cutibacterium acnes pour le traitement d'affections cutanées
CN117165489B (zh) * 2023-09-21 2024-04-19 山东福瑞达生物股份有限公司 一种痤疮丙酸杆菌发酵上清液、制备方法及其应用
EP4559469A1 (fr) 2023-11-22 2025-05-28 Aileens Pharma S.r.l. Compositiones pour le traitement ou la prévention d'une dysbiose

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3580453B2 (ja) * 1995-09-28 2004-10-20 株式会社アドバンス 細胞賦活性化粧料
WO2015106175A1 (fr) * 2014-01-10 2015-07-16 The Regents Of The University Of California Probiotique pour la peau

Also Published As

Publication number Publication date
JP7832676B2 (ja) 2026-03-18
MX2022009744A (es) 2022-11-09
IL295326B1 (en) 2026-03-01
US12508288B2 (en) 2025-12-30
EP4107293A1 (fr) 2022-12-28
IL295326A (en) 2022-10-01
ES2983028T3 (es) 2024-10-21
WO2021165434A1 (fr) 2021-08-26
HRP20240892T1 (hr) 2024-10-11
HUE067226T2 (hu) 2024-10-28
MD4107293T2 (ro) 2024-09-30
US20240024375A1 (en) 2024-01-25
SA522440072B1 (ar) 2023-11-19
BR112022015153A2 (pt) 2022-10-11
PL4107293T3 (pl) 2024-09-30
ZA202208862B (en) 2023-12-20
CN115698258A (zh) 2023-02-03
CA3167099A1 (fr) 2021-08-26
CO2022013143A2 (es) 2022-12-09
IT202000003233A1 (it) 2021-08-18
EP4107293C0 (fr) 2024-04-24
PH12022552059A1 (en) 2024-02-12
AU2021225048A1 (en) 2022-09-01
IL326688A (en) 2026-04-01
RS65788B1 (sr) 2024-08-30
EP4107293B1 (fr) 2024-04-24
JP2023518665A (ja) 2023-05-08
KR20220149543A (ko) 2022-11-08
SMT202400348T1 (it) 2024-11-15

Similar Documents

Publication Publication Date Title
JOP20220179A1 (ar) N4-هيدروكسي سيتيدين ومشتقات واستخدامات مضادة للفيروسات مرتبطة بها
ZA202208862B (en) Cutibacterium acnes strain and medical uses thereof
MA42279B1 (fr) Compositions comprenant une souche bactérienne de blautia hydrogenotrophica pour l'utilisation pour la prevention ou le traitement de la diarrhee ou la constipation
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
TNSN04268A1 (fr) UTILISATION D'INHIBITEURS CETP ET FACULTATIVEMENT D'INHIBITEURS DE HMG -CoA - REDUCTASE ET/OU D'AGENTS ANTI-HYPERTENSIFS
MA27053A1 (fr) Beta-amino tetrahydroimidazo(1,2-a)pyrazines et tetrahydrotriazolo (4,3-a)pyrazines comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
MA44674B1 (fr) Inhibiteurs de bromodomaine
MA40893A (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
MA44851B1 (fr) Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations
TW262461B (fr)
MA39094B1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
IL101761A0 (en) Fatty acid based compositions for the control of established plant infections
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA62917A1 (fr) Composés de lactivicine, leur préparation et leur utilisation en tant qu'agents antibactériens
MA31562B1 (fr) Macrocycles et leurs utilisations
FR3126991B1 (fr) Souche bactérienne dans la prévention et/ou le traitement de pathologies inflammatoires
MA31902B1 (fr) Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque
Sakko et al. Antimicrobial 2‐hydroxyisocaproic acid and chlorhexidine resist inactivation by dentine
FR3065009B1 (fr) Secretome bacterien pour son utilisation dans le traitement des lesions cutanees
Emira et al. In vitro activity of Melaleuca alternifolia (Tea tree) and Eucalyptus globulus essential oils on oral Candida biofilm formation on polymethylmethacrylate
EP4344749A3 (fr) Formulation de protéase pour le traitement d'infections microbiennes
MA54276B1 (fr) Montélukast destinée au traitement de l'arthrose de la main
Reeves et al. Effect of N-chlorotaurine on Aspergillus, with particular reference to destruction of secreted gliotoxin
WO2022254446A1 (fr) Méthode destinée au traitement d'une croissance microbienne excessive, d'un déséquilibre et d'infections
EP4230226A4 (fr) Composition pour le traitement de maladies rétiniennes ou choroïdiennes, contenant un inhibiteur d'acta2 comme principe actif